Updated November 2021 DGL bulletin data—In November, for the whole market, Keytruda still remains in the first place in the ranking. Interestingly, NHF spending on its reimbursement increased by 81.0% compared to 2020, with cumulative reimbursement value from January to November 2021 of 253 million, while the total amount of reimbursement for 2020 was 172 million. The increase may be… Czytaj dalej #TOP10 reimbursement value in Poland – November 2021
Updated October 2021 DGL bulletin dataIn October, for the whole market, Keytrude remains in the first place in the ranking, but NHF spending on its reimbursement increased by 76.5% compared to 2020. Spinraza has dropped two more places (from 4th to 6th) while Xtandi moved to 7th place from 8th, with a 50,8% increase in the amount of… Czytaj dalej #TOP10 reimbursement value in Poland
Does biosimilar competition impact the reimbursement policy of the originator reference products? Given the excessive costs associated with biological and biosimilar drugs, the price behavior of this class of medicines is particularly important from industry and societal perspective. It is known that the availability of biosimilars can lead to rapid price reductions, particularly in markets… Czytaj dalej Does biosimilar competition impact the reimbursement policy of the originator reference products?
In September, there were significant changes in the TOP10 reibursement value for brands. For the whole market, #Keytrude moved to the 1st place from 4th in the ranking, while #Spinraza fell to 4th place. #Opdivo and #Neoparin swapped places – Opdivo moved to 2nd place from 3rd.The total reimbursement value for the current year is… Czytaj dalej TOP10 reimbursement value in Poland – September 2021
For drug programmes, Keytruda moved to the 3rd place in the ranking, for which the reimbursement amount in the period from January to July 2021 is 65.8% higher than the reimbursement value in the corresponding period of the previous year.
The list of medicines of high clinical value, published on August 26, 2021, includes 35 medical technologies – including 30 medicinal products registered by #EMA in 2017-2020. In the period from 01/01/2017 to 31/12/2020, 951 drug technologies (for 321 medicinal products) were registered by EMA. The final list was selected by #AOTMiT from 374 medical technologies (39%) left after… Czytaj dalej MF – The list of medicines of high clinical value
Medical Fund in Poland Due to the Act on the Medical Fund in force we looked into registration drugs in European Medicines Agency (#EMA) to see which products may be included in the upcoming high clinical value drugs list by #AOTMiT. From 2017 to the end of July 2021, 268 new products were registered by EMA,… Czytaj dalej Medical Fund in Poland
Updated May DGL bulletin data NHF spending on medical products, foodstuffs and medical devices reimbursement from February till May 2021 amounted to PLN 5.64 billion, including PLN 3.64 billion on products from #outpatientslist, with the foodstuff – for the first time – Neocate (milk-substitute diet) in 9th place out of the TOP10.
Updated April #DGL bulletin data NHF spending on medical products from drug programmes from January till April 2021 amounted to PLN 1.42 billion and are 18% higher than reimbursement amount in the same period of the previous year. More in our updated IDA TOP10 report.
TOP 10 reimbursement value for brands NHF spending on medical products, foodstuffs and medical devices reimbursement from January till February 2021 amounted to PLN 2.09 billion, including PLN 1.37 billion expenditures on products from outpatients list, PLN 0.65 billion on medical products from drug programmes and PLN 0.07 billion on products from chemotherapy. NHF spending… Czytaj dalej TOP 10 reimbursement value for brands